Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study

Akira Kawai, Hiroyuki Narahara, Shunji Takahashi, Tomoki Nakamura, Hiroshi Kobayashi, Yasunori Megumi, Toshiyuki Matsuoka, Eisuke Kobayashi, Akira Kawai, Hiroyuki Narahara, Shunji Takahashi, Tomoki Nakamura, Hiroshi Kobayashi, Yasunori Megumi, Toshiyuki Matsuoka, Eisuke Kobayashi

Abstract

Background: Soft tissue sarcomas (STSs) are a heterogeneous group of cancers with over 100 described subtypes. While these cancers are infrequent, the prognosis is quite poor, particularly for those with stage IV metastatic disease. Patients for whom curative resection is difficult or those with recurrent metastatic disease are treated with chemotherapy, although the options are very limited. Eribulin is an approved treatment of all STS subtypes in Japan. Efficacy and safety data for the treatment of rare STS subtypes other than liposarcoma and leiomyosarcoma (L-type sarcomas) are limited. This nationwide, multicenter, prospective, post-marketing observational study was conducted to assess the real-world effectiveness and safety of eribulin in Japanese patients with STS.

Methods: Patients with all types of STS and who consented to eribulin treatment were eligible to participate. The observation period was 1 year, starting at treatment initiation, and clinical outcomes were followed up for 2 years after initiating treatment. The primary endpoint was overall survival (OS). Additional outcomes included time-to-treatment failure (TTF), objective response rate (ORR), disease control rate (DCR), and safety. ORR and DCR were evaluated using imaging findings. Effectiveness results were analyzed both for all patients and by STS subtype.

Results: A total of 256 patients were enrolled; 252 and 254 were included in the effectiveness and safety analysis set, respectively. Most patients (83.1%) received an initial eribulin dose of 1.4 mg/m2 (standard dose). Respective median OS (95% confidence interval [CI]) was 10.8 (8.5-13.1), 13.8 (10.1-22.3) and 6.5 (5.7-11.1) months for all, L-type, and non-L-type subtypes. The respective median TTF (95% CI) was 2.5 (2.1-2.8), 2.8 (2.3-3.7), and 2.2 (1.6-2.6) months. The ORR and DCR were 8.1 and 42.6%, respectively. Adverse drug reactions (ADRs) and serious ADRs were reported for 83.5 and 18.9% of patients, respectively. The main ADRs were associated with myelosuppression. No significant difference was observed in the incidence of ADRs for patients ≥65 versus <65 years old.

Conclusions: Eribulin demonstrated effectiveness and a manageable safety profile for patients with STS, although the effectiveness of eribulin was not demonstrated for some non-L-type subtypes.

Trial registration: NCT03058406 ( ClinicalTrials.gov ).

Keywords: Eribulin; Japan; Overall survival; Post-marketing study; Soft tissue sarcoma.

Conflict of interest statement

ST has received grants from Eisai Co., Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co., Ltd.; and honoraria from Eisai Co., Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co., Ltd. EK has received honoraria from Eisai Co., Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co., Ltd. All other authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Patient disposition. AE adverse event

References

    1. Anderson WJ, Doyle LA. Updates from the 2020 World Health Organization classification of soft tissue and bone tumours. Histopathology. 2021;78(5):644–657. doi: 10.1111/his.14265.
    1. Sarcoma Committee of Chinese Anti-Cancer Association, Chinese Society of Clinical Oncology Chinese expert consensus on diagnosis and treatment of soft tissue sarcomas (Version 2015) Chin J Oncol. 2016;38:310–320.
    1. Ministry of Health, Labour and Welfare in Japan, patient survey, 2014. . Accessed 20 July 2021.
    1. Ministry of Health, Labour and Welfare in Japan, Vital Statistics, 2019 . Accessed 20 July 2021.
    1. National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: soft tissue including heart cancer. 2021. . Accessed 22 Mar 2022.
    1. Internal residents in National Cancer Center Japan . Cancer treatment manual for resident staff. 8. Igaku-Shoin; 2019.
    1. Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, Oosterhuis JW, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003;39(1):64–69. doi: 10.1016/S0959-8049(02)00480-X.
    1. Kasper B, Ho AD, Egerer G. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology. 2005;68(2–3):115–121. doi: 10.1159/000085704.
    1. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KM, et al. Soft tissue sarcoma version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(5):536–563. doi: 10.6004/jnccn.2018.0025.
    1. Committee of Diagnosis and Treatment of Soft Tissue Tumors of Japanese Orthopedic Association . Clinical practice guideline on the diagnosis and treatment of soft tissue tumors. 3. Tokyo: Nankodo; 2020.
    1. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group study. J Clin Oncol. 2007;25(21):3144–3150. doi: 10.1200/JCO.2006.09.7717.
    1. van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, et al. Results of randomised studies of the EORTC soft tissue and bone sarcoma group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002;38(18):2397–2406. doi: 10.1016/S0959-8049(02)00491-4.
    1. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423. doi: 10.1016/S1470-2045(14)70063-4.
    1. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886. doi: 10.1016/S0140-6736(12)60651-5.
    1. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188–4196. doi: 10.1200/JCO.2008.21.0088.
    1. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25(19):2755–2763. doi: 10.1200/JCO.2006.10.4117.
    1. García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on sarcomas study. J Clin Oncol. 2011;29(18):2528–2533. doi: 10.1200/JCO.2010.33.6107.
    1. Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445–2452. doi: 10.1158/1078-0432.CCR-14-3252.
    1. Eisai’s anticancer agent Halaven® newly approved in Japan for treatment of soft tissue sarcoma. 2016. . Accessed 20 July 2021.
    1. Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017;47(2):137–144. doi: 10.1093/jjco/hyw175.
    1. Osgood CL, Chuk MK, Teoret MR, Huang L, He K, Her L, et al. FDA approval summary: eribulin for patients with unresectable of metastatic liposarcoma who have received a prior anthracycline-containing regimen. Clin Cancer Res. 2017;23(21):6384–6389. doi: 10.1158/1078-0432.CCR-16-2422.
    1. Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–1637. doi: 10.1016/S0140-6736(15)01283-0.
    1. Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95–104. doi: 10.1097/PAT.0000000000000050.
    1. Kobayashi E, Naito Y, Asano N, Maejima A, Endo M, Takahashi S, et al. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol. 2019;49(10):938–946. doi: 10.1093/jjco/hyz096.
    1. Eisai Inc . Halaven [package insert] 7 2020.
    1. Eisai Inc . Halaven [prescribing information] 2016.
    1. European Medicines Agency. Halaven. 2016. . Accessed 20 July 2021.
    1. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(8):1325–1332. doi: 10.1002/pbc.24517.
    1. Kawano S, Asano M, Adachi Y, Matsui J. Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma. Anticancer Res. 2016;36(4):1553–1561.
    1. De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, et al. Primary culture of undifferentiated pleomorphic sarcoma: molecular characterization and response to anticancer agents. Int J Mol Sci. 2017;18(12):2662. doi: 10.3390/ijms18122662.
    1. Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045–1052. doi: 10.1016/S1470-2045(11)70230-3.
    1. Nakano K, Hayakawa K, Funauchi Y, Tanizawa T, Ae K, Matsumoto S, et al. Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. Mol Clin Oncol. 2021;14(1):13. doi: 10.3892/mco.2020.2175.
    1. Bui NQ, Wang DS, Hiniker SM. Contemporary management of metastatic soft tissue sarcoma. Curr Probl Cancer. 2019;43(4):289–299. doi: 10.1016/j.currproblcancer.2019.06.005.
    1. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–1410. doi: 10.1016/S1470-2045(17)30622-8.
    1. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26(32):5269–5274. doi: 10.1200/JCO.2008.17.3146.
    1. Young RJ, Natukunda A, Litière S, Woll PJ, Wardelmann E, van der Graaf WT. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group trials. Eur J Cancer. 2014;50(18):3178–3186. doi: 10.1016/j.ejca.2014.10.004.
    1. Penel N, Italiano A, Ray-Coquard I, Chaigneau L, Delcambre C, Robin YM, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23(2):517–523. doi: 10.1093/annonc/mdr138.
    1. Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118(13):3330–3336. doi: 10.1002/cncr.26599.
    1. Kim JH, Park HS, Heo SJ, Kim SK, Han JW, Shin KH, et al. Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma. Oncology. 2019;96(2):59–69. doi: 10.1159/000492597.
    1. Kobayashi H, Iwata S, Wakamatsu T, Hayakawa K, Yonemoto T, Wasa J, et al. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: a Japanese musculoskeletal oncology group study. Cancer. 2020;126(6):1253–1263. doi: 10.1002/cncr.32661.
    1. Nakamura T, Tsukushi S, Asanuma K, Katagiri H, Ikuta K, Nagano A, et al. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai musculoskeletal oncology consortium study. Clin Exp Metastasis. 2019;36(4):343–350. doi: 10.1007/s10585-019-09980-3.
    1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens — a European Organization for Research and Treatment of Cancer soft tissue and bone sarcoma group study. J Clin Oncol. 1999;17(1):150–157. doi: 10.1200/JCO.1999.17.1.150.
    1. Elkrief A, Kazandjian S, Alcindor T. Gemcitabine-containing chemotherapy for the treatment of metastatic myxofibrosarcoma refractory to doxorubicin: a case series. Curr Oncol. 2021;28(1):813–817. doi: 10.3390/curroncol28010078.
    1. Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Investig New Drugs. 2017;35(6):791–799. doi: 10.1007/s10637-017-0486-4.
    1. Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241–2248. doi: 10.1007/s00520-017-3631-x.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit